Pfizer Buys 15% Stake in Vivet for €45M, Option to Acquire

March 21, 2019, 1:19 PM

Pfizer has acquired a 15% equity interest in privately held biotech company Vivet Therapeutics for €45 million and secured an exclusive option to buy all outstanding shares.

  • Pfizer & Vivet will collaborate on development of VTX-801 treatment for Wilson disease
  • Pfizer may pay up to €560 million inclusive of option exercise payment & subject to certain milestones
  • Option to buy 100% can be exercised following delivery of data from Phase I/II clinical trial for VTX-801
  • Monika Vnuk, Pfizer VP, Worldwide Development, will join Vivet’s Board of Directors

Link to Statement: Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet...

To read the full article log in. To learn more about a subscription click here.